The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in ...
Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
Virtual reality headsets are being used to help people going through treatment for cystic fibrosis. Patients are immersed in safari experiences and can explore their surroundings as a distraction ...
The initiative, conducted in collaboration with Intellia Therapeutics, aims to develop new treatments for cystic fibrosis (CF), including for patients with genotypes that are non-responsive or ...
Vertex Pharmaceuticals said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of mutations of the ...
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...
The FDA has approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations, according to a press release from Vertex Pharmaceuticals. The FDA has approved ...
A case study on how a pharmaceutical company specializing in cystic fibrosis treatments turned to DelveInsight for comprehensive analysis and insights into the digital cystic fibrosis landscape in ...
A case study on how a pharmaceutical company specializing in cystic fibrosis treatments turned to DelveInsight for comprehensive analysis and insights into the digital cystic fibrosis landscape in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback